Abstract: The invention relates to methods for capturing a polynucleotide comprising a DNA target segment from a population of polynucleotide molecules. The method may use a mixture comprising the population of the polynucleotide molecules, one or more polynucleotide primers, nucleotides, biotinylated nucleotides, a polymerase enzyme and a buffered liquid medium. The method may denature the polynucleotide molecules in the mixture so as to create single stranded portions of the polynucleotide molecules which can be accessible to the polynucleotide primers; hybridizing the polynucleotide primers to the polynucleotide comprising the DNA target segment. The method may create an extended polynucleotide primer by using the nucleotides, the biotinylated nucleotides and the polymerase enzyme as a means for labeling with biotin and increasing the extent of hybridization of the extended polynucleotide primer to the polynucleotide comprising the DNA target segment.

Abstract: The invention relates to methods for capturing a polynucleotide comprising a DNA target segment from a population of polynucleotide molecules using a rotation of a magnetic field to move streptavidin-labeled magnetic beads relative to a buffered liquid medium to increase the probability of capturing and preventing damage to a long polynucleotide comprising a DNA target segment. The methods may use a rotation of the magnetic field relative to the mixture or a rotation of the mixture relative to the magnetic field for causing magnetic bead rotation in the buffered liquid medium and increasing the binding of biotinylated nucleotides of an extended polynucleotide primer to streptavidin-labeled magnetic beads, and winding or condensation of a polynucleotide onto the streptavidin-labeled magnetic beads to prevent damage to the long polynucleotide comprising a DNA target segment.

Abstract: The invention generally relates to a method of regenerating a nerve fiber in a damaged neural tissue of a patient, the method comprising the steps of: administering an aqueous formulation comprising superparamagnetic particles to the damaged neural tissue in the patient; applying a magnetic field in an orientation which is parallel to the nerve fiber; using the magnetic field for aligning the superparamagnetic particles; forming one or more aligned chains of the superparamagnetic particles in the magnetic field as a scaffold to guide directional growth of regenerating nerve cells; and reconnecting damaged nerve ends in the damaged neural tissue of the patient.

Abstract: The invention relates to processes for making pharmaceutical aqueous therapeutic particles (AQTP) having stable exterior water clustering with nanosized thickness less than 300 nanometers, wherein the AQTP has an improved bioavailability when administered to a mammal compared to conventional pharmaceutical drug particles administered to the mammal. The invention relates to an improved process apparatus which is computer controlled, capable of continuous operation with high efficiency so as to make a more consistently acceptable AQTP compared to an previous prototype process apparatus of the Inventors.

Abstract: The invention relates to methods for capturing a polynucleotide comprising a DNA target segment from a population of polynucleotide molecules. The method may use a mixture comprising the population of the polynucleotide molecules, one or more polynucleotide primers, nucleotides, biotinylated nucleotides, a polymerase enzyme and a buffered liquid medium. The method may denature the polynucleotide molecules in the mixture so as to create single stranded portions of the polynucleotide molecules which can be accessible to the polynucleotide primers; hybridizing the polynucleotide primers to the polynucleotide comprising the DNA target segment. The method may create an extended polynucleotide primer by using the nucleotides, the biotinylated nucleotides and the polymerase enzyme as a means for labeling with biotin and increasing the extent of hybridization of the extended polynucleotide primer to the polynucleotide comprising the DNA target segment.

Abstract: The present invention relates to Myosin II ATPase inhibitor compounds, including substituted 3a-hydroxy-1,2,3,3a-tetrahydro-4H-pyrrolo [2,3b] quinolin-4-one compounds which are blebbistatin derivatives.

Abstract: The invention generally relates to a method of regenerating a nerve fiber in a damaged neural tissue of a patient, the method comprising the steps of: administering an aqueous formulation comprising superparamagnetic particles to the damaged neural tissue in the patient; applying a magnetic field in an orientation which is parallel to the nerve fiber; using the magnetic field for aligning the superparamagnetic particles; forming one or more aligned chains of the superparamagnetic particles in the magnetic field as a scaffold to guide directional growth of regenerating nerve cells; and reconnecting damaged nerve ends in the damaged neural tissue of the patient.

Abstract: The present invention relates to Myosin II ATPase inhibitor compounds, including substituted 3a-hydroxy-1, 2, 3, 3a-tetrahydro-4H-pyrrolo [2,3b] quinolin-4-one compounds which are blebbistatin derivatives.

Abstract: A flexible protective medical glove containing a non-liquid antiseptic composition and methods for its use are disclosed. The glove comprises a thin inner layer and a thin outer layer of material; preferably the outer layer is a more elastic and less plastic layer than the inner layer. A compartment between the layers of the glove is capable of providing a non-liquid antiseptic composition which comprises an antiseptic in a non-liquid composition. The non-liquid antiseptic composition may also contain a surface-active agent, an algesic agent, a colorant, a vasoconstrictive agent, an odorant, or a viscosity-modifying agent.

Abstract: A protective medical glove containing a liquid antiseptic composition and methods for its use are disclosed. The flexible glove comprises at least a thin inner layer and at least a thin outer layer of material; the outer layer is preferably the more elastic and less plastic layer. Between the layers of the glove, a liquid antiseptic composition is stored which comprises an antiseptic in a liquid. The liquid antiseptic composition may also contain a surface-active agent, an algesic agent, a colorant, a vasoconstrictive agent, a smell-causing chemical, and a viscosity-modifying agent.